Cardiomyopathy

The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy…

What is this plain language summary about? This summary presents the results from an ongoing, long-term extension studyexternal link, opens in a new tab that…

Background: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of…